BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36759007)

  • 1. Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study.
    Abe K; Furuta S; Kobayashi Y; Sugiyama T; Kagami SI; Nakagomi D; Iwamoto T; Ikeda K; Nakajima H
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36759007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
    Chen F; Li S; Wang T; Shi J; Wang G
    Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review.
    Yeung TW; Cheong KN; Lau YL; Tse KN
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):103. PubMed ID: 34193210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
    Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
    Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
    Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum.
    Yamaguchi K; Yamaguchi A; Itai M; Kashiwagi C; Takehara K; Aoki S; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Takemura M; Hara K; Motegi SI; Muro Y; Nakasatomi M; Sakairi T; Hiromura K; Kurabayashi M; Maeno T
    Clin Rheumatol; 2019 Dec; 38(12):3443-3450. PubMed ID: 31420814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
    Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
    Front Immunol; 2022; 13():879266. PubMed ID: 35603153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.
    Lv C; You H; Xu L; Wang L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
    J Rheumatol; 2023 Feb; 50(2):219-226. PubMed ID: 35705235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases].
    Xie MM; Yan X; Li H; Ding JJ; Gui XH; Liu Y; Wang YS; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Aug; 41(8):616-621. PubMed ID: 30138971
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis.
    Temmoku J; Sato S; Fujita Y; Asano T; Suzuki E; Kanno T; Furuya MY; Matsuoka N; Kobayashi H; Watanabe H; Koga T; Shimizu T; Kawakami A; Migita K
    Medicine (Baltimore); 2019 May; 98(20):e15578. PubMed ID: 31096460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
    Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
    Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
    Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
    PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis /dermatomyositis associated ILD.
    Mao MM; Xia S; Guo BP; Qian WP; Zheng ZX; Peng XM; Chen RC; Luo Q; Han Q
    Respir Med; 2020 Oct; 172():105983. PubMed ID: 33032789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.
    Sato S; Uejima Y; Nanbu M; Suganuma E; Takano T; Tanaka R; Kabuki T; Oguma E; Oh-Ishi T; Kawano Y
    Mod Rheumatol; 2017 Jul; 27(4):652-656. PubMed ID: 27588444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous pneumomediastinum in a dermatomyositis patient with anti-melanoma differentiation-associated gene-5 antibody and interstitial lung disease despite an initial response to immunosuppressant.
    Chan CWS; Chung HY; Lau CS; Tsang HHL
    Int J Rheum Dis; 2019 Mar; 22(3):521-524. PubMed ID: 28580698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.